BRISTOL-MYERS SQUIBB COMPANY | 34,781 Euro | -0,218 -0,62 % | |
| WKN: 850501 ISIN: US1101221083 Ticker-Symbol: BRM | Frankfurt | 19.06.13 | 17:51 Uhr |
Branche PharmaAktienmarkt S&P 100S&P 500 |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 19:34 | An AstraZeneca And Bristol-Myers Diabetes Trial Is A Dud | 3 | Forbes | |
| 16:12 | Pfizer (PFE) Stock Offer, Spinoff Report Sees Fundamental Break-Up Post Zoetis (ZTS); Remember Bristol Myers & Mead Johnson? | 41 | Business Wire | |
| 400m shares are due to hit the market and today's the last day for tendering Pfizer (PFE) common shares in exchange for Zoetis (ZTS) stock. Further, with over 20% upside seen in the next... Mehr lesen zu: Pfizer (PFE) Stock Offer, Spinoff Report Sees Fundamental Break-Up Post Zoetis (ZTS); Remember Bristol Myers & Mead Johnson? | ||||
| 12:31 | Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4 | 6 | StreetInsider.com | |
| 17.06. | Simcere Ties Up with Bristol-Myers | 3 | Zacks | |
| 17.06. | Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals | 12 | PR Newswire | |
| NEW YORK, June 17, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company... Mehr lesen zu: Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals | ||||
| 15.06. | Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study | 4 | Benzinga.com | |
| 15.06. | Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma | 10 | Business Wire | |
| Median progression-free survival (PFS) of 33 months reached after longer-term follow up in patients treated with elotuzumab 10 mg/kg plus lenalidomide and low-dose dexamethasone ... Mehr lesen zu: Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma | ||||
| 15.06. | Beware the Bullishness on Bristol-Myers | 1 | Motley Fool | |
| 14.06. | Bristol-Myers To Partner With Simcere Pharma On Orencia SC In China | 15 | AFX News | |
| NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Bristol-Myers Squibb Co.
(BMY) and China-based Simcere Pharmaceutical Group (SCR) said Thursday that they
have agreed to jointly develop... Mehr lesen zu: Bristol-Myers To Partner With Simcere Pharma On Orencia SC In China | ||||
| 14.06. | Bristol-Myers, Simcere Pharma Expand Strategic Relationship | 9 | AFX News | |
| NEW YORK CITY (dpa-AFX) - Biopharmaceutical companies, Bristol-Myers Squibb
Company (BMY), and Simcere Pharmaceutical Group (SCR) Friday said they have
agreed to collaborate in China on... Mehr lesen zu: Bristol-Myers, Simcere Pharma Expand Strategic Relationship | ||||
| 14.06. | Bristol-Myers, Simcere Announce Partnership to Co-Develop, Co-Commercializde Orencia in China | - | Benzinga.com | |
| 14.06. | Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China | 9 | PR Newswire | |
| PRINCETON, N.J. and NANJING, China, June 14, 2013 /PRNewswire/-- Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today... Mehr lesen zu: Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China | ||||
| 13.06. | Encouraging Data from Bristol-Myers | 6 | Zacks | |
| 12.06. | Look for Shares of Bristol-Myers Squibb to Potentially Rebound after Yesterday's 1.52% Sell Off | 1 | SmarTrend | |
| 12.06. | SmarTrend Watching for Potential Rebound in Shares of Bristol-Myers Squibb After 1.52% Loss | - | SmarTrend | |
| 12.06. | Astrazeneca, Bristol-Myers Squibb Release Statement to American Diabetes Association | 11 | Benzinga.com | |
| 12.06. | Bristol-Myers Squibb Shares Up 13.7% Since SmarTrend's Buy Recommendation | - | SmarTrend | |
| 12.06. | Bristol-Myers' ORENCIA Shows Efficacy In Rheumatoid Arthritis | 31 | AFX News | |
| NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY) Tuesday announced
results of year two data from AMPLE study, a first-of-its-kind trial comparing
the subcutaneous formulation of... Mehr lesen zu: Bristol-Myers' ORENCIA Shows Efficacy In Rheumatoid Arthritis | ||||
| 10.06. | UPDATE 1-Former Bristol-Myers executive admits to insider trading | 3 | Reuters.com | |
| 10.06. | Former Bristol-Myers executive admits to insider trading | 1 | Reuters.com | |
Seite: 1 2 3 4 5 ... Weiter >>
344 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von